Table 1.
Phase II trials of single-agent rituximab in chronic lymphocytic leukemia patients
| Authors | No of evaluable patients | Prior therapy | Rituximab dose (mg/m2) | No of doses | Overall response rate (%) |
|---|---|---|---|---|---|
| McLaughlin et al47 | 30 | Yes | 375 q 4 weeks | 4 | 13 |
| Nguyen et al48 | 10 | Yes | 375 q 4 weeks | 4 | 10 |
| Winkler et al49 | 9 | Yes | 375 q 4 weeks | 4 | 11 |
| Ladetto et al50 | 7 | Yes | 375 q 4 weeks | 4 | 0 |
| Huhn et al9 | 28 | Yes | 375 q 4 weeks | 4 | 25 |
| Thomas et al52 | 21 | No | 375 q 4 weeks | 8 | 90 |
| Itala et al51 | 24 | Yes | 375 q 4 weeks | 4 | 35 |
| Hainsworth et al10 | 44 | No | 375 q 4 weeks | 4 | 51 |